DexCom, Inc. (DXCM)
| Market Cap | 28.68B -15.4% |
| Revenue (ttm) | 4.82B +16.2% |
| Net Income | 930.40M +73.8% |
| EPS | 2.34 +75.5% |
| Shares Out | 385.87M |
| PE Ratio | 30.59 |
| Forward PE | 26.76 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 970,607 |
| Open | 72.00 |
| Previous Close | 71.54 |
| Day's Range | 72.00 - 74.52 |
| 52-Week Range | 54.11 - 89.98 |
| Beta | 1.45 |
| Analysts | Strong Buy |
| Price Target | 85.75 (+15.38%) |
| Earnings Date | Jul 30, 2026 |
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin;... [Read more]
Financial Performance
In 2025, DexCom's revenue was $4.66 billion, an increase of 15.60% compared to the previous year's $4.03 billion. Earnings were $836.30 million, an increase of 45.14%.
Financial StatementsAnalyst Summary
According to 27 analysts, the average rating for DXCM stock is "Strong Buy." The 12-month stock price target is $85.75, which is an increase of 15.38% from the latest price.
News
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
SAN DIEGO--(BUSINESS WIRE)--Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participa...
DexCom selected by FDA as first participant in TEMPO pilot
The U.S. Food and Drug Administration announced the first manufacturer selected for the Technology-Enabled Meaningful Patient Outcomes, or TEMPO, for Digital Health Devices Pilot. The participating ma...
DexCom price target raised to $87 from $80 at Truist
Truist raised the firm’s price target on DexCom (DXCM) to $87 from $80 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…
DexCom price target raised to $90 from $85 at Mizuho
Mizuho raised the firm’s price target on DexCom (DXCM) to $90 from $85 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical device and…
DexCom announces Health Canada authorization for Dexcom G7 15 Day CGM
Dexcom (DXCM) announced that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System, or CGM, for people 18 years and older living with diabetes. Published first…
Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Gluc...
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will...
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
DexCom initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of DexCom (DXCM) with a Buy rating and $86 price target The company “could be turning a corner” as its recent investor day eased concerns around…
DexCom announces milestones to make glucose biosensing more accessible
DexCom (DXCM) announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. The company announced pediatric clearance for the Stelo Gluc...
DexCom initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of DexCom (DXCM) with a Buy rating and $86 price target
Dexcom Further Advances Vision of Glucose Biosensing for All
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucos...
Living Longer Is Big Business. These Stocks Will Benefit.
TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.
DexCom price target raised to $88 from $75 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on DexCom (DXCM) to $88 from $75 and keeps an Overweight rating on the shares. The firm is updating a…
FDA clears first over-the-counter glucose monitor for children
The U.S. Food and Drug Administration said on Friday it has expanded the use of Dexcom's Stelo Glucose Biosensor System to children with diabetes, making it the first over-the-counter continuous glu...
DexCom’s over-the-counter CGM for children cleared for marketing by FDA
The U.S. Food and Drug Administration cleared for marketing the first over-the-counter continuous glucose monitor for children, Dexcom (DXCM) Inc.’s Stelo Glucose Biosensor System, an integrated CGM i...
Pharmsource says it was unaware Dexcom sensors it bought were slated for destruction
Drug wholesaler Pharmsource LLC said it was unaware the Dexcom glucose sensors it bought from licensed distributors had been slated for destruction, after the device maker warned some units were sto...
DexCom price target raised to $95 from $75 at TD Cowen
TD Cowen analyst Joshua Jennings raised the firm’s price target on DexCom (DXCM) to $95 from $75 and keeps a Buy rating on the shares. The firm said the company…
DexCom price target raised to $85 from $75 at Mizuho
Mizuho raised the firm’s price target on DexCom (DXCM) to $85 from $75 and keeps an Outperform rating on the shares after attending the American Diabetes Association meeting. DexCom’s randomized…
DexCom price target raised to $91 from $81 at Raymond James
Raymond James raised the firm’s price target on DexCom (DXCM) to $91 from $81 and keeps a Strong Buy rating on the shares. While acknowledging the high expectations, the CONNECT…
DexCom announces results from CONNECT trial of Dexcom G7
DexCom (DXCM) announced results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in g...
Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study
Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not using insulin, compared with routine care, acc...
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically si...
DexCom price target raised to $90 from $85 at Stifel
Stifel analyst Jonathan Block raised the firm’s price target on DexCom (DXCM) to $90 from $85 and keeps a Buy rating on the shares. The firm’s survey of 35 doctors,…